about
Challenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV ReservoirsTowards an HIV cure based on targeted killing of infected cells: different approaches against acute versus chronic infectionBroadly neutralizing antibody and the HIV reservoir in acute HIV infection: a strategy toward HIV remission?Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor ActivityExpanded cytotoxic T-cell lymphocytes target the latent HIV reservoirLeveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future DirectionsHIV-specific CD8⁺ T cells and HIV eradicationMultilineage polyclonal engraftment of Cal-1 gene-modified cells and in vivo selection after SHIV infection in a nonhuman primate model of AIDSThe clinical applications of genome editing in HIV.HIV cure research: a formidable challengeNew challenges in therapeutic vaccines against HIV infection.Engineering broadly neutralizing antibodies for HIV prevention and therapy.Challenges and strategies for the eradication of the HIV reservoir.Novel immunological strategies for HIV-1 eradicationAntigen recognition-triggered drug delivery mediated by nanocapsule-functionalized cytotoxic T-cells.Cytomegalovirus-Infected Cells Resist T Cell Mediated Killing in an HLA-Recognition Independent Manner.Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells.Refining Current Scientific Priorities and Identifying New Scientific Gaps in HIV-Related Heart, Lung, Blood, and Sleep Research.Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor.Turning the tables on cytomegalovirus: targeting viral Fc receptors by CARs containing mutated CH2-CH3 IgG spacer domains.Quarter Century of Anti-HIV CAR T Cells.HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals
P2860
Q26781511-5C3F0A5E-97CA-4DDB-B1F8-FE1A10A07134Q27005830-DDDB273F-C815-4F71-A3C0-425F2907F468Q35595846-338ADEB6-5248-4940-8E63-3AD30BF8BB36Q35745453-4D6F545C-ACF3-4A65-90BB-F1533DEA8465Q35812943-7622E061-0AE8-45CB-9C65-1FF446FF251CQ36030989-F03EC8E7-3964-4D1A-A5E8-509A91FF2A61Q36515071-7E3EB887-7838-452E-B6F3-73D3B5D42A4AQ36613666-02DC19ED-B70A-44E2-885C-8B166AA89954Q36942032-ECB10180-A1EB-45C3-912E-F0C20BC2FFE7Q37098202-4744C1AA-8F83-45BB-9997-BBA610D87362Q38692205-F6CB6ED1-BA7D-4A49-B7B6-FE62D1639878Q38717198-D6D0AF7E-A928-453E-BD2C-6D16A6C29E41Q38862056-F9840FF8-D8DB-4896-898C-96436502C92AQ38915896-8877C26A-86FD-4B5B-B2F0-DFEE54FF68A6Q39110669-87F75C28-F1CE-45F8-93E5-4CA174EA09B6Q39634413-DC0E5280-81FF-401D-BAB2-81181DF4F1FDQ40084640-E8C443AA-0EFC-49B9-BA68-418F0E94AC4DQ40191380-EBB2B5BD-F947-4BAE-BD6F-EBDD69C2DCE6Q41918232-18D21C16-BE6B-4E63-9A72-A7F8304D2562Q50025140-AE814D1D-9566-46E5-9325-A919FC2988F7Q52676237-CA0A2E9C-8249-47C6-945F-C0049BEB254FQ57039737-90329C75-C37B-4BBC-9CFE-384FA253A757
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
T-cell therapies for HIV
@ast
T-cell therapies for HIV
@en
T-cell therapies for HIV
@nl
type
label
T-cell therapies for HIV
@ast
T-cell therapies for HIV
@en
T-cell therapies for HIV
@nl
prefLabel
T-cell therapies for HIV
@ast
T-cell therapies for HIV
@en
T-cell therapies for HIV
@nl
P2860
P3181
P356
P1433
P1476
T-cell therapies for HIV
@en
P2093
Catherine Bollard
Sharon Lam
P2860
P304
P3181
P356
10.2217/IMT.13.23
P407
P577
2013-04-01T00:00:00Z